Amytrx Therapeutics closed on its final tranche of its Series A capital raise, totaling $18 million to expand on its clinical research on AMTX-100.

Amytrx Therapeutics closed on its final tranche of its Series A capital raise, totaling $18 million to expand on its clinical research investigating AMTX-100, a new cell- penetrating immune system modulating peptide therapeutic for topical skin applications, specifically in atopic dermatitis and other dermatologic indications.

"We are counting on success in our Phase 2 in atopic dermatitis clinical trial as we move forward and begin a seamless transition toward our future goals in other immune mediated disorders," says Amytrx Chief Business Officer Randall Riggs, in a news release. “We also see the promise of a new localized treatment for adolescents with a therapeutic that doesn't suppress the immune system like many topical steroids on the market. Instead, we use a normal cellular process to modulate and bring about resolution to symptoms using molecules containing amino acid sequences already present and easily metabolized by our bodies."

In its development, AMTX-100 has proven to have potential in preclinical and clinical studies addressing AD, and other inflammatory and metabolic diseases with attractive out-licensing and collaborative opportunities in additional inflammatory skin diseases such as psoriasis, rosacea, lupus, acne, shingles, and herpes.

PHOTO CAPTION: Amytrx CEO Dr. Matthew A. Gonda